Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks